The health economics of Helicobacter pylori infection

Boonen, 2004, A tale of two cities: hospitalization costs in 1897 and 1997, Int J Tech Assess Health Care, 20, 236, 10.1017/S0266462304001023 OECD. Health data 2006: statistics and indicators for 30 countries. Organisation for Economic Co-operation and Development; 2006. Palmer, 1999, Economic notes: opportunity cost, BMJ, 318, 1551, 10.1136/bmj.318.7197.1551 Hendricks, 1999, More or less?: Methods to compare VA and non-VA health care costs, Med Care, 37, AS54, 10.1097/00005650-199904002-00008 Briggs, 2001, The death of cost-minimization analysis?, Health Economics, 10, 179, 10.1002/hec.584 Lowson, 1981, Costing new services: long-term domiciliary oxygen therapy, Lancet, i, 1146, 10.1016/S0140-6736(81)92311-4 Rasanen, 2006, Use of quality-adjusted life years for the estimation of effectiveness of health care: A systematic literature review, Int J Technol Assess Health Care, 22, 235, 10.1017/S0266462306051051 Siegel, 1996, Recommendations for reporting cost-effectiveness analyses. Panel on Cost-Effectiveness in Health and Medicine, JAMA, 276, 1339, 10.1001/jama.276.16.1339 Moayyedi, 2005, Gambling with gastroesophageal reflux disease: should we worry about the QALY?, Am J Gastroenterol, 100, 534, 10.1111/j.1572-0241.2005.41779.x Mooney, 1980, Cost-benefit analysis and medical ethics, J Med Ethics, 6, 177, 10.1136/jme.6.4.177 Moayyedi, 2004, Cost-utility and cost-benefit analyses: how did we get here and where are we going?, Eur J Gastroenterol Hepatol, 16, 527, 10.1097/00042737-200406000-00004 Sendi, 2001, Affordability and cost-effectiveness: decision-making on the cost-effectiveness plane, Health Economics, 10, 675, 10.1002/hec.639 Eddy, 2006, Bringing health economic modeling to the 21st century, Value Health, 9, 168, 10.1111/j.1524-4733.2006.00097.x Briggs, 1998, An introduction to Markov modelling for economic evaluation, Pharmacoeconomics, 13, 397, 10.2165/00019053-199813040-00003 Farthing, 1998, Helicobacter pylori infection: an overview, Br Med Bull, 54, 1, 10.1093/oxfordjournals.bmb.a011661 Ford A, Delaney B, Forman D et al. Eradication therapy for peptic ulcer disease in Helicobacter pylori positive patients. Cochrane Database Systemat Rev 4: CD003840, 2004. Ford, 2004, Eradication therapy in Helicobacter pylori positive peptic ulcer disease: systematic review and economic analysis, Am J Gastroenterol, 99, 1833, 10.1111/j.1572-0241.2004.40014.x Briggs, 1996, Cost effectiveness of screening for and eradication of Helicobacter pylori in management of dyspeptic patients under 45 years of age, BMJ, 312, 1321, 10.1136/bmj.312.7042.1321 Sonnenberg, 1998, Cost savings in duodenal ulcer therapy through Helicobacter pylori eradication compared with conventional therapies: results of a randomized, double-blind, multicenter trial. Gastrointestinal Utilization Trial Study Group, Arch Intern Med, 158, 852, 10.1001/archinte.158.8.852 Tavakoli, 1999, Decision analysis of histamine H2-receptor antagonist maintenance therapy versus Helicobacter pylori eradication therapy: a randomised controlled trial in patients with continuing pain after duodenal ulcer, Pharmacoeconomics, 16, 355, 10.2165/00019053-199916040-00004 Groeneveld, 2001, Quality of life measurement clarifies the cost-effectiveness of Helicobacter pylori eradication in peptic ulcer disease and uninvestigated dyspepsia, Am J Gastroenterol, 96, 338, 10.1111/j.1572-0241.2001.03516.x Crawley, 2001, Measuring change in quality of life in response to Helicobacter pylori eradication in peptic ulcer disease: the QOLRAD, Dig Dis Sci, 46, 571, 10.1023/A:1005655317121 Bytzer, 2000, Eradication of Helicobacter pylori compared with long-term acid suppression in duodenal ulcer disease. A randomized trial with 2-year follow-up. The Danish Ulcer Study Group, Scand J Gastroenterol, 35, 1023, 10.1080/003655200451135 Tack, 2006, Functional gastroduodenal disorders, Gastroenterology, 130, 1466, 10.1053/j.gastro.2005.11.059 Bercik, 2002, Immune-mediated neural dysfunction in a murine model of chronic Helicobacter pylori infection, Gastroenterology, 123, 1205, 10.1053/gast.2002.36024 Moayyedi, 2000, Systematic review and economic evaluation of Helicobacter pylori eradication treatment for non-ulcer dyspepsia. Dyspepsia Review Group, BMJ, 321, 659, 10.1136/bmj.321.7262.659 Laine, 2001, Therapy for Helicobacter pylori in patients with nonulcer dyspepsia. A meta-analysis of randomized, controlled trials, Ann Intern Med, 134, 361, 10.7326/0003-4819-134-5-200103060-00008 Moayyedi, 2003, An update of the Cochrane systematic review of Helicobacter pylori eradication therapy in nonulcer dyspepsia: resolving the discrepancy between systematic reviews, Am J Gastroenterol, 98, 2621, 10.1111/j.1572-0241.2003.08724.x Moayyedi P, Soo S, Deeks J et al. Eradication of Helicobacter pylori for non-ulcer dyspepsia. Cochrane Database Systemat Rev 2:CD002096, 2006. Moayyedi, 2004, The efficacy of proton pump inhibitors in nonulcer dyspepsia: a systematic review and economic analysis, Gastroenterology, 127, 1329, 10.1053/j.gastro.2004.08.026 Moayyedi, 2002, Helicobacter pylori eradication in non-ulcer dyspepsia: the case for, 265 Kleinman, 2002, Willingness to pay for complete symptom relief of gastroesophageal reflux disease, Arch Intern Med, 162, 1361, 10.1001/archinte.162.12.1361 Kartman, 2001, Utility and willingness to pay measurements among patients with gastroesophageal reflux disease, Am J Gastroenterol, 96, S38, 10.1016/S0002-9270(01)02581-3 Moayyedi, 2000, The proportion of upper gastrointestinal symptoms in the community associated with Helicobacter pylori, lifestyle factors, and nonsteroidal anti-inflammatory drugs. Leeds HELP Study Group, Am J Gastroenterol, 95, 1448, 10.1111/j.1572-0241.2000.2126_1.x Asante, 1999, Endoscopy for Helicobacter pylori sero-negative young dyspeptic patients: an economic evaluation based on a randomized trial, Eur J Gastroenterol Hepatol, 11, 851, 10.1097/00042737-199908000-00007 Delaney BC & Moayyedi P. Dyspepsia. Health care needs assessment 3rd series. Department of Health, UK; 2003, http://hcna.radcliffe-oxford.com/dysframe.htm. Hallissey, 1990, Early detection of gastric cancer, BMJ, 301, 513, 10.1136/bmj.301.6751.513 Sue-Ling, 1992, Early gastric cancer: 46 cases treated in one surgical department, Gut, 33, 1318, 10.1136/gut.33.10.1318 Veldhuyzen van Zanten, 2005, Canadian Dyspepsia Working Group. Evidence-based recommendations for short- and long-term management of uninvestigated dyspepsia in primary care: an update of the Canadian Dyspepsia Working Group (CanDys) clinical management tool, Can J Gastroenterol, 19, 285, 10.1155/2005/674607 Talley, 2005, American gastroenterological association technical review on the evaluation of dyspepsia, Gastroenterology, 129, 1756, 10.1053/j.gastro.2005.09.020 Talley, 2005, Practice Parameters Committee of the American College of Gastroenterology. Guidelines for the management of dyspepsia, Am J Gastroenterol, 100, 2324, 10.1111/j.1572-0241.2005.00225.x NICE, 2004 Bytzer, 1994, Empirical H2-blocker therapy or prompt endoscopy in management of dyspepsia, Lancet, 343, 811, 10.1016/S0140-6736(94)92023-0 Gisbert, 2004, The TETRA study: a prospective evaluation of Helicobacter pylori ‘test-and-treat’ strategy on 736 patients in clinical practice, Helicobacter, 9, 28, 10.1111/j.1083-4389.2004.00195.x Sreedharan, 2004, Cost-effectiveness and long-term impact of Helicobacter pylori ‘test and treat’ service in reducing open access endoscopy referrals, Eur J Gastroenterol Hepatol, 16, 981, 10.1097/00042737-200410000-00005 Arents, 2003, Approach to treatment of dyspepsia in primary care: a randomized trial comparing: ‘test-and-treat’ with prompt endoscopy, Arch Intern Med, 163, 1606, 10.1001/archinte.163.13.1606 Lassen, 2000, Helicobacter pylori test-and-eradicate versus prompt endoscopy for management of dyspeptic patients: a randomised trial, Lancet, 356, 455, 10.1016/S0140-6736(00)02553-8 McColl, 2002, Randomised trial of endoscopy with testing for Helicobacter pylori compared with non-invasive H. pylori testing alone in the management of dyspepsia, BMJ, 324, 999, 10.1136/bmj.324.7344.999 Duggan, 1999, Does initial management of patients with dyspespsia alter symptom response and patient satisfaction? Results of a randomized trial, Gastroenterology, 116, G0654 Myers P. Personal communication, May 2004. Briggs, 1999, Handling uncertainty when performing economic evaluation of healthcare interventions. Health Technol Assess, Winchester, England, 3, 1 Ford, 2005, Helicobacter pylori “test and treat” or endoscopy for managing dyspepsia: an individual patient data meta-analysis, Gastroenterology, 128, 1838, 10.1053/j.gastro.2005.03.004 Dyspepsia: A national clinical guideline (SIGN 68). Scottish Intercollegiate Guidelines Network, March 2003. Downloaded August 30th 2006, http://www.sign.ac.uk/pdf/sign68.pdf. Allison, 2003, A randomized controlled trial of test-and-treat strategy for Helicobacter pylori: clinical outcomes and health care costs in a managed care population receiving long-term acid suppression therapy for physician-diagnosed peptic ulcer disease, Arch Intern Med, 163, 1165, 10.1001/archinte.163.10.1165 Ladabaum, 2002, Helicobacter pylori test-and-treat intervention compared to usual care in primary care patients with suspected peptic ulcer disease in the United States, Am J Gastroenterol, 97, 3007, 10.1111/j.1572-0241.2002.07118.x Manes, 2003, Empirical prescribing for dyspepsia: randomised controlled trial of test and treat versus omeprazole treatment, BMJ, 326, 1118, 10.1136/bmj.326.7399.1118 Jarbol, 2006, Proton pump inhibitor or testing for Helicobacter pylori as the first step for patients presenting with dyspepsia? A cluster-randomized trial, Am J Gastroenterol, 101, 1200, 10.1111/j.1572-0241.2006.00673.x Chiba, 2002, Treating Helicobacter pylori infection in primary care patients with uninvestigated dyspepsia: the Canadian adult dyspepsia empiric treatment-Helicobacter pylori positive (CADET-Hp) randomised controlled trial, BMJ, 324, 1012, 10.1136/bmj.324.7344.1012 Stevens, 2001, Benefits of Helicobacter pylori eradication in the treatment of ulcer-like dyspepsia in primary care (abstract), Gastroenterology, 120, 260, 10.1016/S0016-5085(01)80247-X Farkkila, 2004, Does the ‘test-and-treat’ strategy work in primary health care for management of uninvestigated dyspepsia? A prospective two-year follow-up study of 1552 patients, Scand JGastroenterol, 39, 327, 10.1080/00365520310008674 Delaney B, Ford AC, Forman D et al. Initial management strategies for dyspepsia. Cochrane Database Systemat Rev 4:CD001961, 2005. Chiba, 2004, Economic evaluation of Helicobacter pylori eradication in the CADET-Hp randomized controlled trial of H. pylori-positive primary care patients with uninvestigated dyspepsia, Aliment Pharmacol Ther, 19, 349, 10.1111/j.1365-2036.2004.01865.x Bytzer, 2006, Management of the dyspeptic patient: anything goes?, Am J Gastroenterol, 101, 1209, 10.1111/j.1572-0241.2006.00666.x Pisani, 2002, Estimates of the world-wide prevalence of cancer for 25 sites in the adult population, Int J Cancer, 97, 72, 10.1002/ijc.1571 Malfertheiner, 2005, Helicobacter pylori eradication has the potential to prevent gastric cancer: A state-of-the-art-critique, Am J Gastroenterol, 100, 2100, 10.1111/j.1572-0241.2005.41688.x Moayyedi, 1997, Helicobacter pylori and gastric cancer: implications for screening, Gastrointestinal Endosc Clin North Am, 7, 47, 10.1016/S1052-5157(18)30322-2 Kuipers, 2004, Cure of Helicobacter pylori infection in patients with reflux oesophagitis treated with long term omeprazole reverses gastritis without exacerbation of reflux disease: results of a randomised controlled trial, Gut, 53, 12, 10.1136/gut.53.1.12 You, 2006, Randomized double-blind factorial trial of three treatments to reduce the prevalence of precancerous gastric lesions, J Natl Cancer Inst, 98, 974, 10.1093/jnci/djj264 Mera, 2005, Long term follow up of patients treated for Helicobacter pylori infection, Gut, 54, 1536, 10.1136/gut.2005.072009 Moayyedi, 2004, Helicobacter pylori public health implications, Helicobacter, 9, 67, 10.1111/j.1083-4389.2004.00250.x Wong, 2004, China Gastric Cancer Study Group. Helicobacter pylori eradication to prevent gastric cancer in a high-risk region of China: a randomized controlled trial, JAMA, 291, 187, 10.1001/jama.291.2.187 Mason, 2002, Leeds HELP Study Group. The cost-effectiveness of population Helicobacter pylori screening and treatment: a Markov model using economic data from a randomized controlled trial, Aliment Pharmacol Ther, 16, 559, 10.1046/j.1365-2036.2002.01204.x Lane, 2006, Impact of Helicobacter pylori eradication on dyspepsia, health resource use, and quality of life in the Bristol helicobacter project: randomised controlled trial, BMJ, 332, 199, 10.1136/bmj.38702.662546.55 Ford, 2005, A community screening program for Helicobacter pylori saves money: 10-year follow-up of a randomized controlled trial, Gastroenterology, 129, 1910, 10.1053/j.gastro.2005.09.016 Roderick, 2003, The cost-effectiveness of screening for Helicobacter pylori to reduce mortality and morbidity from gastric cancer and peptic ulcer disease: a discrete-event simulation model, Health Technol Assess (Winchester, England), 7, 1 Leivo, 2004, Cost-benefit analysis of Helicobacter pylori screening, Health Policy, 70, 85, 10.1016/j.healthpol.2004.02.004 Rupnow, 1999, Helicobacter pylori vaccine development and use: a cost-effectiveness analysis using the Institute of Medicine Methodology, Helicobacter, 4, 272, 10.1046/j.1523-5378.1999.99311.x Parsonnet, 1996, Modelling cost-effectiveness of Helicobacter pylori screening to prevent gastric cancer: a mandate for clinical trials, Lancet, 348, 150, 10.1016/S0140-6736(96)01501-2 Sonnenberg, 2002, What to do about Helicobacter pylori? A decision analysis of its implication on public health, Helicobacter, 7, 60, 10.1046/j.1523-5378.2002.00057.x Sonnenberg, 1998, Review article: Medical decision models of Helicobacter pylori therapy to prevent gastric cancer. Aliment Pharmacol Ther, 12, 111 Harris, 1999, Helicobacter pylori and gastric cancer: what are the benefits of screening only for the CagA phenotype of H. pylori?, Helicobacter, 4, 69, 10.1046/j.1523-5378.1999.98057.x